Prospective, Multicenter Clinical Study of Prolonged-release Tacrolimus in Stable Pediatric Liver Transplant Recipients

Recruiting N/A Interventional Study
Liver Transplant
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
6 Months – 18
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
80 (estimated)
Sponsor
RenJi Hospital · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

This study aims to explore the effects of tacrolimus sustained-release capsules on the incidence of biopsy-proven acute rejection(BPAR) and fibrosis in pediatric liver transplant recipients.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Children (≤18 years old) who have undergone liver transplantation, with no gender limitations; 2. Able to completely swallow capsules; 3. Have been using immediate-release tacrolimus for at least three months prior to study enrollment; 4. Have normal blood count, liver and ki…
Contacts

Hao Feng, MD., Ph.D

008615000901110

surgeonfeng@live.com

CONTACT